SCHEMBL6415959

SCHEMBL6415959

NN=C(c1ccc(-c2cccc(C(=O)O)c2)o1)c1nc2nonc2nc1Nc1ccc(F)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BIRC5 O15392 1/20 0.42
RPA1 P27694 1/20 0.41
CSNK2A1 P68400 12/20 0.40
CSNK2A2 P19784 2/20 0.40
CSNK2B P67870 2/20 0.40
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
POLB P06746 2/20 0.39
MAPT P10636 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
MEN1 O00255 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.37
C3AR1 Q16581 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6415096 0.94 AURKA (0.38) BIRC5RPA1ALDH1A1POLBMAPT
SCHEMBL6419747 0.93 BIRC5 (0.43) BIRC5RPA1ALDH1A1KDM4EPOLB
SCHEMBL6414872 0.91 RPA1 (0.43) RPA1CSNK2A1CSNK2A2CSNK2BALDH1A1
SCHEMBL6431830 0.90 BIRC5 (0.44) BIRC5CSNK2A1CSNK2A2CSNK2BALDH1A1
SCHEMBL6434895 0.90 BIRC5 (0.45) BIRC5CSNK2A1ALDH1A1KDM4EPOLB
SCHEMBL6432253 0.88 RPA1 (0.44) RPA1CSNK2A1CSNK2A2CSNK2BALDH1A1
SCHEMBL6415701 0.88 CSNK2A1 (0.45) CSNK2A1CSNK2A2CSNK2BPOLBMAPT
SCHEMBL6415683 0.88 CSNK2A1 (0.45) CSNK2A1CSNK2A2CSNK2BPOLBMAPT
SCHEMBL6413428 0.88 BIRC5 (0.47) BIRC5CSNK2A1CSNK2A2CSNK2BALDH1A1
SCHEMBL6416017 0.86 KDR (0.38) BIRC5RPA1ALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 BIRC5 2525/4885RPA1 3166/4885CSNK2A1 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.